OTCPK:DIZT.F

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Dignitana AB (publ.), a medical technology company, develops, produces, and markets medical cooling devices primarily in the United States. More Details


Snowflake Analysis

Worrying balance sheet with weak fundamentals.

Share Price & News

How has Dignitana AB (publ.)'s share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: DIZT.F's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

DIZT.F

0.6%

US Medical Equipment

0.09%

US Market


1 Year Return

13.5%

DIZT.F

14.8%

US Medical Equipment

12.6%

US Market

Return vs Industry: DIZT.F underperformed the US Medical Equipment industry which returned 15.4% over the past year.

Return vs Market: DIZT.F matched the US Market which returned 13.6% over the past year.


Shareholder returns

DIZT.FIndustryMarket
7 Day0%0.6%0.09%
30 Day27.0%0.9%-1.6%
90 Day56.9%11.4%7.9%
1 Year13.5%13.5%15.8%14.8%15.2%12.6%
3 Year-43.2%-43.2%72.3%67.9%38.9%29.6%
5 Year-52.0%-52.0%148.2%129.3%87.6%66.5%

Price Volatility Vs. Market

How volatile is Dignitana AB (publ.)'s share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Dignitana AB (publ.) undervalued compared to its fair value and its price relative to the market?

13.17x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate DIZT.F's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate DIZT.F's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: DIZT.F is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: DIZT.F is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DIZT.F's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DIZT.F is overvalued based on its PB Ratio (13.2x) compared to the US Medical Equipment industry average (3.9x).


Next Steps

Future Growth

How is Dignitana AB (publ.) forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

26.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Dignitana AB (publ.) has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of DIZT.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on theOTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Dignitana AB (publ.)'s filings and announcementshere.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Dignitana AB (publ.) performed over the past 5 years?

-0.08%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DIZT.F is currently unprofitable.

Growing Profit Margin: DIZT.F is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: DIZT.F is unprofitable, and losses have increased over the past 5 years at a rate of 0.08% per year.

Accelerating Growth: Unable to compare DIZT.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DIZT.F is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.2%).


Return on Equity

High ROE: DIZT.F has a negative Return on Equity (-139.29%), as it is currently unprofitable.


Next Steps

Financial Health

How is Dignitana AB (publ.)'s financial position?


Financial Position Analysis

Short Term Liabilities: DIZT.F's short term assets (SEK24.9M) do not cover its short term liabilities (SEK33.3M).

Long Term Liabilities: DIZT.F's short term assets (SEK24.9M) exceed its long term liabilities (SEK5.9M).


Debt to Equity History and Analysis

Debt Level: DIZT.F's debt to equity ratio (48.3%) is considered high.

Reducing Debt: Insufficient data to determine if DIZT.F's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DIZT.F has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: DIZT.F has less than a year of cash runway if free cash flow continues to reduce at historical rates of 10.8% each year


Next Steps

Dividend

What is Dignitana AB (publ.) current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate DIZT.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DIZT.F's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DIZT.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DIZT.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DIZT.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Bill Cronin (55 yo)

no data

Tenure

kr1,711,000

Compensation

Mr. William Cronin, also known as Bill, has been the Chief Executive Officer of Dignitana Inc. since November 8, 2016. Mr. Cronin serves as the Chief Executive Officer and Director of Dignitana AB.


CEO Compensation Analysis

Compensation vs Market: Bill's total compensation ($USD0.00) is below average for companies of similar size in the US market ($USD595.72K).

Compensation vs Earnings: Insufficient data to compare Bill's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
William Cronin
CEO & Directorno datakr1.71mno data
Anette Cronstroem
Executive Officerno datakr107.00kno data
Thomas Joyce
Executive Officerno datakr107.00kno data
James McKinney
President & COO2.5yrsno datano data
Jonas Sohlman
Interim Chief Financial Officer0.67yrno datano data
Melissa Bourestom
VP of Corporate Communicationsno datano datano data
Cameron O'Mara
Vice President Global Sales1.67yrsno datano data
Jane Wall
Director of Clinical Servicesno datano datano data

1.7yrs

Average Tenure

55yo

Average Age

Experienced Management: DIZT.F's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
William Cronin
CEO & Directorno datakr1.71mno data
Pontus Kristiansson
Independent Director1.67yrsno datano data
Ljubo Mrnjavac
Director0.25yrno datano data
Ingrid Heiman
Independent Director2.5yrskr201.00kno data
Christian Lindgren
Director0.25yrno datano data
Klas Arildsson
Independent Chairman of Board0.25yrno datano data
Richard DiIorio
Independent Director0.25yrno datano data

0.3yrs

Average Tenure

55yo

Average Age

Experienced Board: DIZT.F's board of directors are not considered experienced ( 0.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.3%.


Top Shareholders

Company Information

Dignitana AB (publ.)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Dignitana AB (publ.)
  • Ticker: DIZT.F
  • Exchange: OTCPK
  • Founded: 2007
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr449.283m
  • Listing Market Cap: kr51.027m
  • Shares outstanding: 55.06m
  • Website: https://dignitana.com

Number of Employees


Location

  • Dignitana AB (publ.)
  • Traktorgränden 3
  • Lund
  • Skåne County
  • 226 60
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DIGNOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKJun 2009
DIZT.FOTCPK (Pink Sheets LLC)YesShare CapitalUSUSDJun 2009

Biography

Dignitana AB (publ.), a medical technology company, develops, produces, and markets medical cooling devices primarily in the United States. It offers DigniCap, a scalp cooling system used to reduce hair lo ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/19 07:38
End of Day Share Price2020/09/04 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.